Vipin Garg, Altimmune CEO

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

Among the al­so-rans in the Covid-19 vac­cine race, small biotech Al­tim­mune hoped to ride a nov­el in­tranasal for­mu­la­tion for its own can­di­date to mar­ket but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.